BRPI0612752B8 - composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano - Google Patents

composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano

Info

Publication number
BRPI0612752B8
BRPI0612752B8 BRPI0612752A BRPI0612752A BRPI0612752B8 BR PI0612752 B8 BRPI0612752 B8 BR PI0612752B8 BR PI0612752 A BRPI0612752 A BR PI0612752A BR PI0612752 A BRPI0612752 A BR PI0612752A BR PI0612752 B8 BRPI0612752 B8 BR PI0612752B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
solid pharmaceutical
pyridylmethylaminomethyl
chroman
fluorophenyl
Prior art date
Application number
BRPI0612752A
Other languages
English (en)
Inventor
Heil Kirstin
Kunath Klaus
Rupp Roland
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0612752A2 publication Critical patent/BRPI0612752A2/pt
Publication of BRPI0612752B1 publication Critical patent/BRPI0612752B1/pt
Publication of BRPI0612752B8 publication Critical patent/BRPI0612752B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano. a presente invenção refere-se a uma composição farmacêutica sólida contendo (r)-(-)-2-[5-(fluorfenil)-3-piridilmetilaminometil]cromano como uma substância ativa, pelo menos um álcool de açúcar (por exemplo, manitol, sorbitol) como uma carga, e para a fabricação de composição farmacêutica sólida. a composição tem uma vida de prateleira aumentada, também em temperaturas elevadas e pode ser usada para o tratamento de discinesia associada com doença de parkison.
BRPI0612752A 2005-06-21 2006-06-09 composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano BRPI0612752B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05013293.5 2005-06-21
EP05013293 2005-06-21
PCT/EP2006/005563 WO2006136302A1 (de) 2005-06-21 2006-06-09 Feste pharmazeutische zubereitung enthaltend (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman

Publications (3)

Publication Number Publication Date
BRPI0612752A2 BRPI0612752A2 (pt) 2010-11-30
BRPI0612752B1 BRPI0612752B1 (pt) 2019-08-20
BRPI0612752B8 true BRPI0612752B8 (pt) 2021-05-25

Family

ID=36809668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612752A BRPI0612752B8 (pt) 2005-06-21 2006-06-09 composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano

Country Status (17)

Country Link
US (1) US8093270B2 (pt)
EP (1) EP1896021B1 (pt)
JP (1) JP5139275B2 (pt)
KR (1) KR101306088B1 (pt)
CN (1) CN101198328B (pt)
AR (1) AR054487A1 (pt)
AT (1) ATE428416T1 (pt)
AU (1) AU2006261314B2 (pt)
BR (1) BRPI0612752B8 (pt)
CA (1) CA2612738C (pt)
DE (1) DE502006003465D1 (pt)
ES (1) ES2322777T3 (pt)
MX (1) MX2007015359A (pt)
PT (1) PT1896021E (pt)
RU (1) RU2405547C2 (pt)
WO (1) WO2006136302A1 (pt)
ZA (1) ZA200800553B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101978953A (zh) * 2010-10-11 2011-02-23 上海交通大学 基于易吸湿性辅料的固体制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327077A (en) * 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
JPH1053529A (ja) * 1996-06-07 1998-02-24 Takeda Chem Ind Ltd 固形製剤
JPH10203971A (ja) * 1996-11-19 1998-08-04 Takeda Chem Ind Ltd 水性経口液剤
JPH11189547A (ja) * 1997-12-26 1999-07-13 Taisho Pharmaceut Co Ltd 安定化されたニコランジル製剤及びその製造方法
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
JP4063390B2 (ja) * 1998-03-06 2008-03-19 三菱商事フードテック株式会社 錠剤の製造方法
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
JP3595765B2 (ja) * 2000-09-27 2004-12-02 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤
PT1343518E (pt) * 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
DE10120619A1 (de) * 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman

Also Published As

Publication number Publication date
CN101198328B (zh) 2011-04-06
AR054487A1 (es) 2007-06-27
DE502006003465D1 (de) 2009-05-28
RU2008101364A (ru) 2009-07-27
US8093270B2 (en) 2012-01-10
JP5139275B2 (ja) 2013-02-06
ES2322777T3 (es) 2009-06-26
EP1896021B1 (de) 2009-04-15
BRPI0612752A2 (pt) 2010-11-30
RU2405547C2 (ru) 2010-12-10
ZA200800553B (en) 2008-12-31
ATE428416T1 (de) 2009-05-15
KR101306088B1 (ko) 2013-09-09
AU2006261314A1 (en) 2006-12-28
KR20080030029A (ko) 2008-04-03
MX2007015359A (es) 2008-02-15
PT1896021E (pt) 2009-07-20
CN101198328A (zh) 2008-06-11
AU2006261314B2 (en) 2012-03-22
CA2612738A1 (en) 2006-12-28
BRPI0612752B1 (pt) 2019-08-20
JP2008543894A (ja) 2008-12-04
CA2612738C (en) 2013-11-26
WO2006136302A1 (de) 2006-12-28
EP1896021A1 (de) 2008-03-12
US20100105648A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
ES2524771T3 (es) Composiciones farmacéuticas que comprenden levetiracetam y procedimientos para su preparación
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
PE20100252A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
ECSP088239A (es) Composición de liberación de fármaco sostenida
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
UY29149A1 (es) Tiazolil-dihidro-indazoles
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
DOP2011000094A (es) Formulacion farmaceutica 514
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
BRPI0813450B8 (pt) composto, formulação farmacêutica, e, usos do composto
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0507198A (pt) derivados de bisariluréia
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
BRPI0715712B8 (pt) composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
BR112013028744A2 (pt) cocristais de ácido cítrico e de l-prolina de (2s,3r,4r,5s,6r)-2(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetra-hidro-2h-piran-3,4,5-triol
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2674 DE 05-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.